The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma
Singapore medical journal
; : 55-71, 2017.
Article
in En
| WPRIM
| ID: wpr-304130
Responsible library:
WPRO
ABSTRACT
Multiple myeloma (MM) is an incurable plasma cell neoplasm with an incidence of 100 patients per year in Singapore. Major advances have been made in the diagnosis, risk stratification and treatment of MM in the recent past. The reclassification of a subset of patients with smouldering MM, based on high-risk biomarkers, and the development of the revised international staging system are among the key new developments in diagnosis and staging. The use of novel agent-based treatment has resulted in significant improvements in the survival and quality of life of many patients with MM. Determining the optimal use of proteasome inhibitors, immunomodulators and, more recently, monoclonal antibodies is an area of ongoing investigation. In this guideline, we aim to provide an overview of the management of MM, incorporating the latest developments in diagnosis and treatment.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Quality of Life
/
Reference Standards
/
Singapore
/
Societies, Medical
/
Therapeutics
/
Biomarkers, Tumor
/
Chemistry
/
Risk
/
Practice Guidelines as Topic
/
Transplantation Conditioning
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Guideline
Aspects:
Patient_preference
Limits:
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
En
Journal:
Singapore medical journal
Year:
2017
Document type:
Article